References
- Archer R. A., Stark P., Lemberger L. Nabilone. Cannabinoids as Therapeutic Agents., R. Mechoulam. CRC Press, Boca Raton, Fla 1986; 85–104, 1986
- Burns J. J., Salvador R. A., Lemberger L. Metabolic Blockade by Methoxamine and Its Analogs. Annals of the New York Academy of Science 1967; 139: 879–890
- Fagius J., Osterman P. O., Siden A., Wiholm B. E. Guillain-Barre syndrome following zimelidine treatment. Journal of Neurology, Neurosurgery, and Psychiatry 1985; 48: 65–69
- Herman T. S., Einhorn L. H., Jones S. E., Nagy C., Chester A. B., Dean J. C., Furnas B., Williams S. D., Leigh S. A., Dorr R. T., Moon T. E. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. New England Journal of Medicine. 1979; 300: 1295–1297
- Jaffe J. H., Martin W. R. Opioid Analgesics and Antagonists. The Pharmacological Basis of Therapeutics. 7th ed., L. Goodman, A. Gilman. Macmillan, New York 1985; 491–531
- Levine R. J., Sjoerdsma A. Estimation of Monoamine Oxidase Activity in Man: Techniques and Applications. Annals of the New York Academy of Science 1963; 107: 966–974
- Rubin A., Lemberger L., Warrick P., Crabtree R. E., Sullivan H., Rowe H., Obermeyer B. D. Physiologic disposition of nabilone, a cannabinol derivative, in man. Clinical Pharmacology & Therapeutics 1977; 22: 85–91